Mouse Xenograft Models for Drug Discovery in Pancreatic Cancer

  • Belen Rubio-Viqueira
  • Manuel HidalgoEmail author


It is estimated that the development of a new anticancer agent costs US $800–1,000 million and takes over a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns whether such models are predictive of drug efficacy in humans, supporting the development of alternative approaches. Furthermore, a general transition has been observed from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to target-orientated drug screening of agents with defined mechanisms of action. New approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamic and pharmacokinetic properties of the tested drug. This chapter focuses on the classical and new preclinical screening models and techniques for anticancer drug development.


Pancreatic Cancer Xenograft Model Antitumor Efficacy Human Tumor Xenograft Humanize Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Assersohn L, Gangi L, Zhao Y et al (2002) The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res 8:794–801PubMedGoogle Scholar
  2. Bankert RB, Egilmez NK, Hess SD (2001) Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 22:386–393CrossRefPubMedGoogle Scholar
  3. Baselga J, Tripathy D, Mendelsohn J et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744PubMedGoogle Scholar
  4. Basu GD, Pathangey LB, Tinder TL et al (2004) Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2:632–642PubMedGoogle Scholar
  5. Bearss DJ, Subler MA, Hundley JE et al (2000) Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 19:1114–1122CrossRefPubMedGoogle Scholar
  6. Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40:852–857CrossRefPubMedGoogle Scholar
  7. Bishop PC, Myers T, Robey R et al (2002) Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21:119–127CrossRefPubMedGoogle Scholar
  8. Bocsi J, Zalatnai A (1999) Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability in morphology, DNA ploidy and proliferation activity. J Cancer Res Clin Oncol 125:9–19CrossRefPubMedGoogle Scholar
  9. Boyd M (1997). The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985–1995. In: Teicher BA (ed) Anticancer drug development guide:preclinical screening, clinical trials, and approval. Humana Press, Totowa, p 23Google Scholar
  10. Campiglio M, Locatelli A, Olgiati C et al (2004) Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 198:259–268CrossRefPubMedGoogle Scholar
  11. Chudnovsky Y, Adams AE, Robbins PB et al (2005) Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37:745–749CrossRefPubMedGoogle Scholar
  12. De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200:429–447CrossRefPubMedGoogle Scholar
  13. Decker S, Hollingshead M, Bonomi CA et al (2004) The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer 40:821–826CrossRefPubMedGoogle Scholar
  14. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185CrossRefPubMedGoogle Scholar
  15. Donelli MG, Rosso R, Garattini S (1967) Selective chemotherapy in relation to the site of tumor transplantation. Int J Cancer 2:421–424CrossRefPubMedGoogle Scholar
  16. Eccles S (2002). Models for evaluation of targeted therapies of metastatic disease. In Teicher BA (eds) Tumor models in cancer research. Humana Press, Totowa, pp 293–319Google Scholar
  17. El Hilali N, Rubio N, Martinez-Villacampa M et al (2002) Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab Invest 82:1563–1571PubMedGoogle Scholar
  18. Engelholm SA, Vindelov LL, Spang-Thomsen M et al (1985) Genetic instability of cell lines derived from a single human small cell carcinoma of the lung. Eur J Cancer Clin Oncol 21:815–824CrossRefPubMedGoogle Scholar
  19. Fichtner I, Slisow W, Gill J et al (2004) Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40:298–307CrossRefPubMedGoogle Scholar
  20. Fidler IJ, Wilmanns C, Staroselsky A et al (1994) Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 13:209–222CrossRefPubMedGoogle Scholar
  21. Fiebig HH, Maier A, Burger AM (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40:802–820CrossRefPubMedGoogle Scholar
  22. Flanagan SP (1966) 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet Res 8:295–309CrossRefPubMedGoogle Scholar
  23. Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360–5364PubMedGoogle Scholar
  24. Goldin A, Venditti JM, Kline I et al (1960) Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. II. Cancer Res 20(5):382–469PubMedGoogle Scholar
  25. Goldin A, Venditti JM, Kline I et al (1961) Evaluation of chemical agents against carcinoma CA-755 in mice. Cancer Res 21:617–691PubMedGoogle Scholar
  26. Graham C, Tucker C, Creech J et al (2006) Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 12:223–234CrossRefPubMedGoogle Scholar
  27. Habu S, Fukui H, Shimamura K et al (1981) In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 127:34–38PubMedGoogle Scholar
  28. Hahn SA, Greenhalf B, Ellis I et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221CrossRefPubMedGoogle Scholar
  29. Hausser HJ, Brenner RE (2005) Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun 333:216–222CrossRefPubMedGoogle Scholar
  30. Hoffman R (2002) Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol 3:546–556CrossRefPubMedGoogle Scholar
  31. Hollingshead MG, Alley MC, Camalier RF et al (1995) In vivo cultivation of tumor cells in hollow fibers. Life Sci 57:131–141CrossRefPubMedGoogle Scholar
  32. Inaba M, Kobayashi T, Tashiro T et al (1989) Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer 64:1577–1582CrossRefPubMedGoogle Scholar
  33. Inaba M, Tashiro T, Kobayashi T et al (1988) Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents. Jpn J Cancer Res 79:517–522PubMedGoogle Scholar
  34. Jacks T (1996) Tumor suppressor gene mutations in mice. Annu Rev Genet 30:603–636CrossRefPubMedGoogle Scholar
  35. Jemal A, Murray T, Samuels A et al (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5–26CrossRefPubMedGoogle Scholar
  36. Jimeno A, Solomon A, Karikari C, Garrido-Laguna I, Trusty D, Hruban R, Schulick R, Cameron J, Maitra A, Hidalgo M (2008). A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA). ASCO Annual Meeting. Abstract 4500Google Scholar
  37. Johnson JI, Decker S, Zaharevitz D et al (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424–1431CrossRefPubMedGoogle Scholar
  38. Kelland LR (2004) Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40:827–836CrossRefPubMedGoogle Scholar
  39. Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2:S134–139PubMedGoogle Scholar
  40. Killion JJ, Radinsky R, Fidler IJ (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17:279–284CrossRefPubMedGoogle Scholar
  41. Kim JB, Stein R, O'Hare MJ (2005) Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 26:173–185CrossRefPubMedGoogle Scholar
  42. Lamb J, Crawford ED, Peck D et al (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935CrossRefPubMedGoogle Scholar
  43. Legrand N, Weijer K, Spits H (2006) Experimental models to study development and function of the human immune system in vivo. J Immunol 176:2053–2058PubMedGoogle Scholar
  44. Lin WC, Pretlow TP, Pretlow TG et al (1990) Bacterial lacZ gene as a highly sensitive marker to detect micrometastasis formation during tumor progression. Cancer Res 50:2808–2817PubMedGoogle Scholar
  45. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMedGoogle Scholar
  46. Moore MJ, Hamm J, Dancey J et al (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296–3302CrossRefPubMedGoogle Scholar
  47. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMedGoogle Scholar
  48. Pegram MD, Pauletti G, Slamon DJ (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52:65–77CrossRefPubMedGoogle Scholar
  49. Pelosi G, Bresaola E, Rodella S et al (1994) Expression of proliferating cell nuclear antigen, Ki-67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: an immunochemical study with clinical, pathobiological, and histologic correlations. Diagn Cytopathol 11:131–140CrossRefPubMedGoogle Scholar
  50. Perez-Soler R, Kemp B, Wu QP et al (2000) Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6:4932–4938PubMedGoogle Scholar
  51. Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40:837–844CrossRefPubMedGoogle Scholar
  52. Plowman J (1997). Human tumor xenograft models in NCI drug development. Humana Press, TotowaGoogle Scholar
  53. Pusztai L, Ayers M, Stec J et al (2003) Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9:2406–2415PubMedGoogle Scholar
  54. Rego EM, He LZ, Warrell RP Jr et al (2000) Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 97:10173–10178CrossRefPubMedGoogle Scholar
  55. Rubio-Viqueira B, Jimeno A, Cusatis G et al (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652–4661CrossRefPubMedGoogle Scholar
  56. Rubio-Viqueira B, Mezzadra H, Nielsen ME et al (2007) Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Mol Cancer Ther 6:515–523CrossRefPubMedGoogle Scholar
  57. Rygaard J, Povlsen CO (1969) Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathol Microbiol Scand 77:758–760CrossRefPubMedGoogle Scholar
  58. Sausville EA, Feigal E (1999) Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. Ann Oncol 10:1287–1291CrossRefPubMedGoogle Scholar
  59. Schein PS, Scheffler B (2006) Barriers to efficient development of cancer therapeutics. Clin Cancer Res 12:3243–3248CrossRefPubMedGoogle Scholar
  60. Sebastiani V, Ricci F, Rubio-Viqueira B et al (2006) Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12:2492–2497CrossRefPubMedGoogle Scholar
  61. Sharpless NE, Depinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741–754CrossRefPubMedGoogle Scholar
  62. Simpson-Abelson MR, Sonnenberg GF, Takita H et al (2008) Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol 180:7009–7018PubMedGoogle Scholar
  63. Smith-Jones PM, Solit DB, Akhurst T et al (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701–706CrossRefPubMedGoogle Scholar
  64. Sorio C, Bonora A, Orlandini S et al (2001) Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch 438:154–158CrossRefPubMedGoogle Scholar
  65. Stock CC, Clarke DA, Philips FS et al (1960) Cancer chemotherapy screening data. V. Sarcoma 180 screening data. Cancer Res 20(3):1–192Google Scholar
  66. Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11:971–981PubMedGoogle Scholar
  67. Takimoto CH (2001) Why drugs fail: of mice and men revisited. Clin Cancer Res 7:229–230PubMedGoogle Scholar
  68. Talmadge JE, Meyers KM, Prieur DJ et al (1980) Role of NK cells in tumour growth and metastasis in beige mice. Nature 284:622–624CrossRefPubMedGoogle Scholar
  69. Tan A. JA, Rubio-Viqueira B, Hidalgo M (2008) NCI-60 gene set connectivity map (GS-CMAP): Connecting pathway-based gene expression profiles for therapeutic efficacy determination. J Clin Oncol 26 (May 20 suppl; abstr 3588)Google Scholar
  70. Tan M, Fang HB, Tian GL et al (2005) Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med 24:109–119CrossRefPubMedGoogle Scholar
  71. Thomsen M, Yacoub-Youssef H, Marcheix B (2005) Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo. Tissue Antigens 66:73–82CrossRefPubMedGoogle Scholar
  72. Van Cutsem E, van de Velde H, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438CrossRefPubMedGoogle Scholar
  73. van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508–7515CrossRefPubMedGoogle Scholar
  74. Van Dyke T, Jacks T (2002) Cancer modeling in the modern era: progress and challenges. Cell 108:135–144CrossRefPubMedGoogle Scholar
  75. Venditti JM, Wesley RA, Plowman J (1984) Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976–1982, and future directions. Adv Pharmacol Chemother 20:1–20CrossRefPubMedGoogle Scholar
  76. Von Hoff DD (1998) There are no bad anticancer agents, only bad clinical trial designs – twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4:1079–1086Google Scholar
  77. Wang X, Fu X, Brown PD et al (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726–4728PubMedGoogle Scholar
  78. Weiss B, Shannon K (2003) Mouse cancer models as a platform for performing preclinical therapeutic trials. Curr Opin Genet Dev 13:84–89CrossRefPubMedGoogle Scholar
  79. Weissleder R (2002) Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2:11–18CrossRefPubMedGoogle Scholar
  80. Williams SS, Chen FA, Kida H et al (1996) Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J Immunol 156:1908–1915PubMedGoogle Scholar
  81. Yoshimura M, Endo S, Hioki K et al (1997) Chemotherapeutic profiles of human tumors implanted in SCID mice showing appreciable inconsistencies with those in nude mice. Exp Anim 46:153–156CrossRefPubMedGoogle Scholar
  82. Zubrod CG (1972) The national program for cancer chemotherapy. JAMA 222:1161–1162CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.The Sidney Kimmel Comprehensive Cancer CenterThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations